Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 29, 2013, Pages 12018-12023

  Yang, Yunlong ^a,b   Zhang, Yin ^a   Cao, Ziquan ^c   Ji, Hong ^a   Yang, Xiaojuan ^a   Iwamoto, Hideki ^a   Wahlberg, Eric ^c   Länne, Toste ^c   Sun, Baocun ^d   Cao, Yihai ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b FUDAN UNIVERSITY   (China)

^c LINKÖPING UNIVERSITY   (Sweden)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Antiangiogenic Therapy; Off Tumor Targets; Vascular Homeostasis; Vessel Regression

Indexed keywords

BD 0801; LIOTHYRONINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BD 0801; MONOCLONAL ANTIBODY DC101; NEUTRALIZING ANTIBODY; THYROID HORMONE; THYROXINE; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACCUMULATION; CAVEOLA; CONTROLLED STUDY; DENSITY; DRUG SAFETY; ENDOCRINE GLAND; ENDOTHELIUM CELL; FEMALE; FEMALE GENITAL SYSTEM; FENESTRATION; GASTROINTESTINAL TRACT; INTESTINE VILLUS; KIDNEY; LIOTHYRONINE BLOOD LEVEL; LIVER; MOUSE; NONHUMAN; PANCREAS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; THYROID CELL; THYROID FUNCTION; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL; UTERUS; VASCULAR DISEASE; VASCULARIZATION;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; OFF-TUMOR TARGETS; VASCULAR HOMEOSTASIS; VESSEL REGRESSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; APOPTOSIS; BLOTTING, WESTERN; CAVEOLAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GASTROINTESTINAL TRACT; GENITALIA, FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID GLAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880379660     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1301331110     Document Type: Article

References (50)

1. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285 (21):1182-1186.
2. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342.
3. Senger DR, et al. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983-985.
4. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935):1306-1309.
5. Coultas L, Chawengsaksophak K, Rossant J (2005) Endothelial cells and VEGF in vascular development. Nature 438(7070):937-945.
6. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407 (6801):249-257.
7. Yancopoulos GD, et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242-248.
8. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-676.
9. Cao Y (2009) Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2(59):re1.
10. Sato Y, et al. (2000) Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann N Y Acad Sci 902:201-205, discussion 205-207.
11. Witmer AN, Dai J, Weich HA, Vrensen GF, Schlingemann RO (2002) Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 50(6):767-777.
12. LeCouter J, et al. (2001) Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412(6850):877-884.
13. Vittet D, Ciais D, Keramidas M, De Fraipont F, Feige JJ (2000) Paracrine control of the adult adrenal cortex vasculature by vascular endothelial growth factor. Endocr Res 26 (4):843-852.
14. Eriksson A, et al. (2003) Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability. Circulation 107(11):1532-1538.
15. Kamba T, et al. (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290(2):H560-H576.
16. Ignoffo RJ (2004) Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 61(21, Suppl 5) S21-S26.
17. Miklos GL (2012) Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med 366(17):1638, author reply 1639-1640.
18. Mountzios G, Pentheroudakis G (2012) Bevacizumab in ovarian cancer. N Engl J Med 366(13):1257, author reply 1258.
19. Sculier JP, Meert AP, Paesmans M (2007) Bevacizumab for non-small-cell lung cancer. N Engl J Med 356(13):1373-1374, author reply 1374-1375.
20. Sharieff W (2004) Bevacizumab in colorectal cancer. N Engl J Med 351(16):1690-1691; author reply 1690-1691.
21. Sonpavde G (2003) Bevacizumab in renal-cell cancer. N Engl J Med 349(17):1674.
22. Yu Y, et al. (2010) A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS ONE 5(2):e9072.
23. Xue Y, et al. (2008) Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-Associated systemic syndrome. Proc Natl Acad Sci USA 105 (47):18513-18518.
24. Zhang D, et al. (2011) Antiangiogenic agents significantly improve survival in tumorbearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc Natl Acad Sci USA 108(10):4117-4122.
25. Cao R, et al. (2010) VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancerassociated retinopathy. Proc Natl Acad Sci USA 107(2):856-861.
26. Garon EB, et al. (2012) A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-smallcell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): Treatment rationale and study design. Clin Lung Cancer 13(6):505-509.
27. Fan L, Iseki S (1998) Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 61(1):17-28.
28. Palade GE, Simionescu M, Simionescu N (1979) Structural aspects of the permeability of the microvascular endothelium. Acta Physiol Scand Suppl 463:11-32.
29. Renkin EM (1979) Relation of capillary morphology to transport of fluid and large molecules: A review. Acta Physiol Scand Suppl 463:81-91.
30. Wong ET, Brem S (2011) Taming glioblastoma by targeting angiogenesis: 3 years later. J Clin Oncol 29(2):124-126.
31. Friedman HS, et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740.
32. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039-2049.
33. Lièvre A, Landi B, Mitry E, Taïeb J (2008) [Antiangiogenic agents and gastrointestinal cancers]. Gastroenterol Clin Biol 32(5 Pt 1):504-520.
34. Spratlin JL, Mulder KE, Mackey JR (2010) Ramucirumab (IMC-1121B): A novel attack on angiogenesis. Future Oncol 6(7):1085-1094.
35. Spratlin JL, et al. (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28(5):780-787.
36. Ramlau R, et al. (2012) Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: A randomized, controlled phase III trial. J Clin Oncol 30(29):3640-3647.
37. Motzer RJ, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115-124.
38. Escudier B, et al.; TARGET Study Group (2007) Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 356(2):125-134.
39. Bramwell VH (2012) Pazopanib and the treatment palette for soft-tissue sarcoma. Lancet 379(9829):1854-1856.
40. des Guetz G, Uzzan B, Chouahnia K, Morère JF (2011) Cardiovascular toxicity of antiangiogenic drugs. Target Oncol 6(4):197-202.
41. Randall LM, Monk BJ (2010) Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117(3):497-504.
42. Tol J, et al. (2008) Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 26(4):393-397.
43. Rini BI (2011) Review: Thyroid function abnormalities in patients receiving VEGFtargeted therapy. Clin Adv Hematol Oncol 9(4):337-338.
44. Mancuso MR, et al. (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116(10):2610-2621.
45. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104(43):17069-17074.
46. Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398): 843-845.
47. Makino Y, et al. (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414(6863):550-554.
48. Launay-Vacher V, Deray G (2009) Hypertension and proteinuria: A class-effect of antiangiogenic therapies. Anticancer Drugs 20(1):81-82.
49. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-Analysis. Am J Kidney Dis 49(2):186-193.
50. Perren TJ, et al.; ICON7 Investigators (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484-2496.